Clinical Parameters to Predict Future Clinical Disease Activity After Treatment Change to Higher-Dose Subcutaneous Interferon Beta-1a From Other Platform Injectables in Patients With Relapsing-Remitting Multiple Sclerosis
2012 ◽
Vol 78
(Meeting Abstracts 1)
◽
pp. PD5.008-PD5.008
2016 ◽
Vol 34
(1)
◽
pp. 77-79
1997 ◽
Vol 103
(1)
◽
pp. 99
2013 ◽
Vol 115
◽
pp. S65-S69
◽